152 related articles for article (PubMed ID: 17874453)
21. Analysis of the BRAFV600E mutation in 19 cases of Langerhans cell histiocytosis in Japan.
Sasaki Y; Guo Y; Arakawa F; Miyoshi H; Yoshida N; Koga Y; Nakashima K; Kurita D; Niino D; Seto M; Ohshima K
Hematol Oncol; 2017 Sep; 35(3):329-334. PubMed ID: 27041734
[TBL] [Abstract][Full Text] [Related]
22. Kick it up a Notch: NOTCH1 activation in T-ALL.
Gridley T
Cancer Cell; 2004 Nov; 6(5):431-2. PubMed ID: 15542425
[TBL] [Abstract][Full Text] [Related]
23. [Characteristics of NOTCH1 mutation in adult T-cell acute lymphoblastic leukemia].
Lin ZK; Zhang R; Ge Z; Liu J; Guo X; Qiao C; Wu YJ; Qiu HR; Zhang JF; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1403-8. PubMed ID: 24370020
[TBL] [Abstract][Full Text] [Related]
24. CDKN2A/B Deletion and Double-hit Mutations of the MAPK Pathway Underlie the Aggressive Behavior of Langerhans Cell Tumors.
Xerri L; Adélaïde J; Popovici C; Garnier S; Guille A; Mescam-Mancini L; Laurent C; Brousset P; Coze C; Michel G; Chaffanet M; Bouabdallah R; Coso D; Bertucci F; Birnbaum D
Am J Surg Pathol; 2018 Feb; 42(2):150-159. PubMed ID: 29194093
[TBL] [Abstract][Full Text] [Related]
25. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells.
Allen CE; Li L; Peters TL; Leung HC; Yu A; Man TK; Gurusiddappa S; Phillips MT; Hicks MJ; Gaikwad A; Merad M; McClain KL
J Immunol; 2010 Apr; 184(8):4557-67. PubMed ID: 20220088
[TBL] [Abstract][Full Text] [Related]
26. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
[TBL] [Abstract][Full Text] [Related]
27. Pathogenesis of Langerhans cell histiocytosis.
Badalian-Very G; Vergilio JA; Fleming M; Rollins BJ
Annu Rev Pathol; 2013 Jan; 8():1-20. PubMed ID: 22906202
[TBL] [Abstract][Full Text] [Related]
28. No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies.
da Costa CE; Szuhai K; van Eijk R; Hoogeboom M; Sciot R; Mertens F; Björgvinsdóttir H; Debiec-Rychter M; de Krijger RR; Hogendoorn PC; Egeler RM; Annels NE
Genes Chromosomes Cancer; 2009 Mar; 48(3):239-49. PubMed ID: 19051326
[TBL] [Abstract][Full Text] [Related]
29. Histiocytosis following T-acute lymphoblastic leukemia: a BFM study.
Trebo MM; Attarbaschi A; Mann G; Minkov M; Kornmüller R; Gadner H
Leuk Lymphoma; 2005 Dec; 46(12):1735-41. PubMed ID: 16263575
[TBL] [Abstract][Full Text] [Related]
30. An unusual co-occurrence of Langerhans cell histiocytosis and Rosai-Dorfman disease: report of a case and review of the literature.
Cohen-Barak E; Rozenman D; Schafer J; Krausz J; Dodiuk-Gad R; Gabriel H; Shani-Adir A
Int J Dermatol; 2014 May; 53(5):558-63. PubMed ID: 23968608
[TBL] [Abstract][Full Text] [Related]
31. NOTCH1 mutations are associated with favourable long-term prognosis in paediatric T-cell acute lymphoblastic leukaemia: a retrospective study of patients treated on BCH-2003 and CCLG-2008 protocol in China.
Gao C; Liu SG; Zhang RD; Li WJ; Zhao XX; Cui L; Wu MY; Zheng HY; Li ZG
Br J Haematol; 2014 Jul; 166(2):221-8. PubMed ID: 24690100
[TBL] [Abstract][Full Text] [Related]
32. New insights into the pathogenesis of Langerhans cell histiocytosis.
de Graaf JH; Egeler RM
Curr Opin Pediatr; 1997 Feb; 9(1):46-50. PubMed ID: 9088755
[TBL] [Abstract][Full Text] [Related]
33. JAK2-mutated Langerhans cell histiocytosis associated with primary myelofibrosis treated with ruxolitinib.
Bonometti A; Bagnoli F; Fanoni D; Venegoni L; Corti L; Bianchi P; Elli EM; Isimbaldi G; L'Imperio V; Nazzaro G; Passoni E; Berti E
Hum Pathol; 2018 Mar; 73():171-175. PubMed ID: 29107666
[TBL] [Abstract][Full Text] [Related]
34. Activating Notch1 mutations in mouse models of T-ALL.
O'Neil J; Calvo J; McKenna K; Krishnamoorthy V; Aster JC; Bassing CH; Alt FW; Kelliher M; Look AT
Blood; 2006 Jan; 107(2):781-5. PubMed ID: 16166587
[TBL] [Abstract][Full Text] [Related]
35. Deregulated NOTCH signaling in acute T-cell lymphoblastic leukemia/lymphoma: new insights, questions, and opportunities.
Aster JC
Int J Hematol; 2005 Nov; 82(4):295-301. PubMed ID: 16298817
[TBL] [Abstract][Full Text] [Related]
36. Activating BRAF V600E mutation in aggressive pediatric Langerhans cell histiocytosis: demonstration by allele-specific PCR/direct sequencing and immunohistochemistry.
Méhes G; Irsai G; Bedekovics J; Beke L; Fazakas F; Rózsa T; Kiss C
Am J Surg Pathol; 2014 Dec; 38(12):1644-8. PubMed ID: 25118810
[TBL] [Abstract][Full Text] [Related]
37. A Case of Pulmonary Langerhans Cell Sarcoma Simultaneously Diagnosed with Cutaneous Langerhans Cell Histiocytosis Studied by Whole-Exome Sequencing.
Kim SW; Choi MK; Han HS; Song H; Koh Y; Son SM; Lee OJ; Lee JY; Lee KM; Lee KH; Kwon J
Acta Haematol; 2017; 138(1):24-30. PubMed ID: 28614815
[TBL] [Abstract][Full Text] [Related]
38. NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL.
Sulis ML; Williams O; Palomero T; Tosello V; Pallikuppam S; Real PJ; Barnes K; Zuurbier L; Meijerink JP; Ferrando AA
Blood; 2008 Aug; 112(3):733-40. PubMed ID: 18411416
[TBL] [Abstract][Full Text] [Related]
39. Genomic Alterations in Langerhans Cell Histiocytosis.
Rollins BJ
Hematol Oncol Clin North Am; 2015 Oct; 29(5):839-51. PubMed ID: 26461146
[TBL] [Abstract][Full Text] [Related]
40. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
